{"product_id":"alternatives-to-blood-transfusion-in-transfusion-medicine-isbn-9781405163217","title":"Alternatives to Blood Transfusion in Transfusion Medicine","description":"Meeting the needs of patients while minimizing blood transfusions requires special expertise, precise monitoring and innovative techniques. This cutting-edge resource covers all the important clinical aspects of transfusion medicine in diverse clinical settings, with a special emphasis on alternatives to transfusion.  \u003cp\u003eEdited by a multidisciplinary team consisting of a transfusion specialist, an anesthesiologist and an intensive care specialist this book is endorsed by the Network for Advancement of Transfusion Alternatives. The contributors review the appropriate use of fluids and of blood products, and describe the latest treatment options available to decrease the need for allogeneic blood products including:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eArgon beam\u003c\/li\u003e \u003cli\u003eCell saver\u003c\/li\u003e \u003cli\u003eHarmonic scalpel\u003c\/li\u003e \u003cli\u003eNormovolemic haemodilution\u003c\/li\u003e \u003cli\u003eSynthetic erythropoietin\u003c\/li\u003e \u003cli\u003eAntifibrinolytics\u003c\/li\u003e \u003cli\u003eRecombinant factor VIIa\u003c\/li\u003e \u003cli\u003eAdvanced monitoring of hemostasis\u003c\/li\u003e \u003cli\u003eIntravenous iron\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe new edition is a key reference source for all those involved in the practice of blood management and conservation.\u003c\/p\u003e \u003cp\u003eContributors List ix\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 History and Development of Transfusion Medicine 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 From Blood Transfusion to Transfusion Medicine 3\u003cbr\u003e\u003ci\u003eAlice Maniatis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Allogeneic Blood Usage—Risks and Benefits 9\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e2 Allogeneic Blood Components 11\u003cbr\u003e\u003ci\u003eRebecca Cardigan \u0026amp; Sheila MacLennan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Current Information on the Infectious Risks of Allogeneic Blood Transfusion 21\u003cbr\u003e\u003ci\u003eAlan D. Kitchen \u0026amp; John A. J. Barbara\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Immunological Complications of Blood Transfusion 31\u003cbr\u003e\u003ci\u003eClare Taylor Cristina Navarrete \u0026amp; Marcela Contreras\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Immunomodulation and Allogeneic Blood Transfusion 47\u003cbr\u003e\u003ci\u003eMarloes Waanders Leo Van De Watering \u0026amp; Anneke Brand\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Pathogen Inactivation of Blood Components 60\u003cbr\u003e\u003ci\u003eChris Prowse\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 The Benefits of Allogeneic Erythrocyte Transfusion: What Evidence Do We Have? 68\u003cbr\u003e\u003ci\u003eNeil Soni \u0026amp; Benjamin Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Volume Replacement 83\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 1 Plasma and Albumin 85\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8 Plasma and Albumin 87\u003cbr\u003e\u003ci\u003ePhilippe L. Baele\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Crystalloids and Synthetic Colloids 109\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e9 Pharmacology of Intravenous Fluids 111\u003cbr\u003e\u003ci\u003eMichael F.M. James\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Crystalloids versus Colloids: The Controversy 119\u003cbr\u003e\u003ci\u003eHengo Haljamäe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Effects of Synthetic Colloids on Hemostasis 137\u003cbr\u003e\u003ci\u003eSibylle A. Kozek-Langenecker \u0026amp; Gisela Scharbert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Hydroxyethyl Starch and Renal Dysfunction 150\u003cbr\u003e\u003ci\u003eLaurent Jacob Nicholas Heming \u0026amp; Bertrand Guidet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Choice of a Synthetic Colloid for Surgery 158\u003cbr\u003e\u003ci\u003eJoachim Boldt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Choice of Colloid for Intensive Care Patients 168\u003cbr\u003e\u003ci\u003eYasser Sakr \u0026amp; Yalcin Inel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Hypertonic Saline Solutions for the Initial Treatment of Patients with Traumatic Injuries 179\u003cbr\u003e\u003ci\u003eCharles E. Wade \u0026amp; Michael A. Dubick\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Hyperchloremic Acidosis 194\u003cbr\u003e\u003ci\u003eEdward Burdett \u0026amp; Andre Vercueil\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Tolerance of Anemia 203\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e17 Basic Principles of Oxygen Transport and Calculations 205\u003cbr\u003e\u003ci\u003eJean-Louis Vincent Pongdhep Theerawit \u0026amp; Davide Simion\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Assessment of Tissue Oxygenation 210\u003cbr\u003e\u003ci\u003eMichael Piagnerelli Ann Dierick \u0026amp; Philippe Van der Linden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Tissue Oxygenation and Blood Transfusion 218\u003cbr\u003e\u003ci\u003eStefan Suttner \u0026amp; Joachim Boldt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Anemia and Cardiovascular Disease 229\u003cbr\u003e\u003ci\u003eAntonis S. Manolis Spyridon Koulouris Kostas Triantafyllou Dimitris Sakellariou Sokratis Pastromas \u0026amp; Helen Melita\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Perioperative Hemostasis 253\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21 Monitoring of Hemostasis in the Perioperative Setting 255\u003cbr\u003e\u003ci\u003eSibylle A. Kozek-Langenecker \u0026amp; Eva Schaden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Antifibrinolytics in Open-Heart Surgery 267\u003cbr\u003e\u003ci\u003eWulf Dietrich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients 278\u003cbr\u003e\u003ci\u003eJean-François Hardy Sylvain Bélisle \u0026amp; Philippe Van der Linden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Transfusion Triggers 293\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24 Role of Hemoglobin\/Hematocrit 295\u003cbr\u003e\u003ci\u003eKristine J. Guleserian Hae W. Kim Bruce Pearce Arkadiy Pitman \u0026amp; A. Gerson Greenburg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e25 Calculation of Blood Loss 303\u003cbr\u003e\u003ci\u003eMark E. Brecher\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Management of Massive Transfusion 313\u003cbr\u003e\u003ci\u003eJean-François Hardy \u0026amp; Marc Samama\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7 Alternatives to Allogeneic Blood Transfusion 329 Section 1 Pharmaceutical Approaches 331\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e27 Iron Deficiency: Causes Diagnosis and Management 335\u003cbr\u003e\u003ci\u003eManuel Muñoz José Antonio García-Erce \u0026amp; Elvira Bisbe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Current Status of Perisurgical Erythropoietin Therapy 350\u003cbr\u003e\u003ci\u003eLawrence T. Goodnough\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Erythropoietin and Iron Therapy in Patients with Renal Failure 357\u003cbr\u003e\u003ci\u003eLucia Del Vecchio \u0026amp; Francesco Locatelli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Hemoglobin-based Blood Substitutes 368\u003cbr\u003e\u003ci\u003eG. Deby-Dupont Bernadette Remy \u0026amp; Maurice Lamy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e31 Perfluorocarbon Emulsions 380\u003cbr\u003e\u003ci\u003ePedro Cabrales\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 2 Surgical Techniques 389\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e32 Minimally Invasive Cardiac Surgery: Impact on Blood Loss and Transfusion 391\u003cbr\u003e\u003ci\u003eHe Tao \u0026amp; Fraser Rubens\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Adjunctive Strategies to Impact Blood Transfusion in Cardiac Surgery 408\u003cbr\u003e\u003ci\u003eL. Ressler \u0026amp; Fraser Rubens\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 3 Anesthetic Techniques 419\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e34 Anesthetic Techniques to Reduce Blood Loss 421\u003cbr\u003e\u003ci\u003eDafydd Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 Controlled Hypotension Decreases Blood Transfusion Requirement: Fact or Fallacy? 430\u003cbr\u003e\u003ci\u003eRichard P. Dutton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Acute Normovolemic Hemodilution 439\u003cbr\u003e\u003ci\u003eJavad Bidgoli \u0026amp; Philippe Van der Linden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Hyperoxic Hemodilution 450\u003cbr\u003e\u003ci\u003eJens Meier Konrad Messmer \u0026amp; Oliver Habler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Intraoperative and Postoperative Cell Salvage 458\u003cbr\u003e\u003ci\u003eErnil Hansen \u0026amp; Hans Gombotz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eSection 4 Special Settings 475\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e39 Anemia and Red Blood Transfusion in Critical Care 477\u003cbr\u003e\u003ci\u003eTim Walsh\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e40 Red Blood Cell Transfusions and Alternatives to Treat the Anemia of Prematurity 490\u003cbr\u003e\u003ci\u003eRonald G. Strauss\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Transfusion Alternatives in Orthopedic Surgery 498\u003cbr\u003e\u003ci\u003eManuel Muñoz José Antonio García-Erce \u0026amp; Jorge Cuenca\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Transfusion Alternatives in Obstetrics 509\u003cbr\u003e\u003ci\u003eChristian Breymann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8 Legal and Ethical Issues in Transfusion Medicine 521\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e43 Ethical Aspects of Informed Consent: American Models 523\u003cbr\u003e\u003ci\u003eRonald E. Domen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Blood Transfusions Jehovah’s Witnesses and the American Patients’ Rights Movement 531\u003cbr\u003e\u003ci\u003eCharles H. Baron\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 9 Cost Issues 557\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e45 The Cost and Cost-Effectiveness of Allogeneic and Autologous Blood 559\u003cbr\u003e\u003ci\u003eBrian Custer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Autologous Blood Predonation in Cardiac Surgery 569\u003cbr\u003e\u003ci\u003eWulf Dietrich\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 Cost-Effectiveness of Pharmacological Alternatives 575\u003cbr\u003e\u003ci\u003eDean Fergusson \u0026amp; Brian Hutton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 581\u003c\/p\u003e  \"It would be of great interest to students or practitioners in laboratory and\/or transfusion medicine, anesthesiology, and surgery interested in alternatives to blood transfusion. The editors and authors are credible authorities in their fields.\" (Doody's, 9 September 2011)  \u003cp\u003e\"The book provides the state of the art in blood transfusion management and I shall certainly be referring to it often as I continue to develop a blood conservation programme in my own hospital.\" (The Bulletin of the Royal College of Pathologists, 1 July 2011)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e  \u003cb\u003eProfessor Alice Maniatis\u003c\/b\u003e, Haematology Department of Internal Medicine, University of Greece, Athens, Greece and former President of Network for Advancement of Transfusion Alternatives (NATA).  \u003cp\u003e\u003cb\u003eDr Jean-Francois Hardy\u003c\/b\u003e, Department of Anesthesia, Montreal Heart Institute, Quebec, Canada and on the Board of Directors of NATA.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eDr Phillipe van der Linden\u003c\/b\u003e, Department of Anesthesiology and Intensive Care, Brussels, Belguim and on the Board of Directors of NATA.\u003c\/p\u003e  Meeting the needs of patients while minimizing blood transfusions requires special expertise, precise monitoring and innovative techniques. This cutting-edge resource covers all the important clinical aspects of transfusion medicine in diverse clinical settings, with a special emphasis on alternatives to transfusion.  \u003cp\u003eEdited by a multidisciplinary team consisting of a transfusion specialist, an anesthesiologist and an intensive care specialist this book is endorsed by the Network for Advancement of Transfusion Alternatives. The contributors review the appropriate use of fluids and of blood products, and describe the latest treatment options available to decrease the need for allogeneic blood products including:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eArgon beam\u003c\/li\u003e \u003cli\u003eCell saver\u003c\/li\u003e \u003cli\u003eHarmonic scalpel\u003c\/li\u003e \u003cli\u003eNormovolemic haemodilution\u003c\/li\u003e \u003cli\u003eSynthetic erythropoietin\u003c\/li\u003e \u003cli\u003eAntifibrinolytics\u003c\/li\u003e \u003cli\u003eRecombinant factor VIIa\u003c\/li\u003e \u003cli\u003eAdvanced monitoring of hemostasis\u003c\/li\u003e \u003cli\u003eIntravenous iron\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThe new edition is a key reference source for all those involved in the practice of blood management and conservation.\u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47988716699877,"sku":"NP9781405163217","price":215.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405163217.jpg?v=1761781311","url":"https:\/\/k12savings.com\/products\/alternatives-to-blood-transfusion-in-transfusion-medicine-isbn-9781405163217","provider":"K12savings","version":"1.0","type":"link"}